FOLH1 and prostate carcinoma: LAVA-1207 targets the Vδ2 chain of Vγ9Vδ2-T cells and prostate-specific membrane antigen (PSMA) on prostate cancer cells, inducing potent T cell-mediated lysis of cancer cells while sparing normal cells [6].